

DAFTAR PUSTAKA

- Armandi, A., Rosso, C., Younes, R., Leeming, D.J., Karsdal, M.A., Caviglia, G.P., Nuria, P., Amato, D.D., Abdulle, A., Nicolosi, A., Castelnuevo, G., Saracco, G.M., Ribaldone, D.G., Bugianesi, E., 2023. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease 1–10.
- Bera, C., Hamdan-Perez, N., Patel, K., 2024. Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients. *J. Clin. Med.* 13. <https://doi.org/10.3390/jcm13041046>
- Chen, Q., 2025. Superior Diagnostic Efficacy of N-Terminal Propeptide of Type III Collagen and Golgi Protein 73 for Detection of Fibrosis in Chronic Hepatitis B Patients. <https://doi.org/10.1002/mco2.70236>
- Chen, Z., Ma, Y., Cai, J., Sun, M., Zeng, L., Wu, F., Zhang, Y., Hu, M., 2025. Serum biomarkers for liver fibrosis. *Clin. Chim. Acta* 537, 16–25. <https://doi.org/10.1016/j.cca.2022.09.022>
- Devarbhavi, H., Asrani, S.K., Arab, J.P., Nartey, Y.A., Pose, E., Kamath, P.S., 2023. Global burden of liver disease: 2023 update. *J. Hepatol.* 79, 516–537. <https://doi.org/10.1016/j.jhep.2023.03.017>
- Drysdale, M., Gillespie, I.A., Christensen, D., Davies, J., Woods, K., Roadknight, G., 2025. Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels : A Cross- Sectional Study 1–17. <https://doi.org/10.1111/jvh.70101>
- Erhardtsen, E., Rasmussen, D.G.K., Frederiksen, P., Leeming, D.J., Shevell, D., Gluud, L., Karsdal, M.A., Aithal, G.P., Schattenberg, J.M., 2021. Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis Authors. <https://doi.org/10.1016/j.jhepr.2021.100317>
- Eslam, M., Gao, J., Ming, F., Yu, L., Wai, V., Wong, S., Homer, I., Chun, C., Liu, J., 2025. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction - associated fatty liver disease, *Hepatology International*. Springer India. <https://doi.org/10.1007/s12072-024-10774-3>
- Gheorghe, G., Bungău, S., Ceobanu, G., Ilie, M., Bacalbaşa, N., Bratu, O.G., Vesa, C.M., Găman, M.A., Diaconu, C.C., 2021. The non-invasive assessment of hepatic fibrosis. *J. Formos. Med. Assoc.* 120, 794–803. <https://doi.org/10.1016/j.jfma.2020.08.019>
- Huang, X., Zheng, X., Wang, K., District, H.L., 2025. staging in patients with chronic hepatitis B 17, 1–10. <https://doi.org/10.4240/wjgs.v17.i10.106414>
- Jiang, C., Xu, Z., Liu, J., Li, R., Chen, K., Peng, W., 2025. Noninvasive diagnosis of significant liver fibrosis in patients with chronic hepatitis B using nomogram and machine learning models 1–12.
- Johansen, S., Israelsen, M., Thorhauge, K.H., Hansen, J.K., Hansen, C.D., Schnefeld, H.L., Andersen, P., Villesen, I., Bech, K.T., Detlefsen, S., Torp, N., Leeming, D., Thiele, M., Krag, A., Karsdal, M., 2026. Fibrosis activity vs . disease stage : Complementary and independent predictors of outcomes in alcohol-related liver disease Highlights : Fibrosis activity vs . disease stage : Complementary and independent predictors of outcomes in alcohol-related liver disease q. *J. Hepatol.* 8, 101746. <https://doi.org/10.1016/j.jhepr.2026.101746>

- Kalaiyarasi, K., Sanchalika, A., Min, L.H., Ming, Y.W., Vishalkumar, S., 2024. Transient Elastography Is the Best-Performing Non-Invasive Test of Liver Fibrosis in Obese Asian Patients with Non-Alcoholic Fatty Liver Disease : A Pilot , Cross-Sectional Study 1–12.
- Kim, K., 2024. Transient elastography for assessing liver fibrosis in autoimmune liver diseases : Excellent performance but limited details : Editorial on “ Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver.
- Lassen, P.B., Nori, N., Bedossa, P., Genser, L., Poitou, C., Surabattula, R., Juul, M., Karsdal, M.A., Leeming, D.J., Lassen, P.B., Nori, N., Bedossa, P., Genser, L., Aron-wisnewsky, J., 2021. surgery To cite this version : ce pt e d cr t.
- Liguori, A., Zoncapè, M., Casazza, G., Easterbrook, P., Tsochatzis, E.A., 2025. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines : a systematic review and meta-analysis 10. [https://doi.org/10.1016/S2468-1253\(24\)00437-0](https://doi.org/10.1016/S2468-1253(24)00437-0)
- Liu, X., Xu, J., Rosenthal, S., Zhang, L., Mccubbin, R., Meshgin, N., Shang, L., Koyama, Y., Ma, H., Sharma, S., Heinz, S., Glass, C.K., Benner, C., Brenner, D.A., Kisseleva, T., 2020. Identification of Lineage-Specific Transcription Factors That Prevent Activation of Hepatic Stellate Cells and Promote Fibrosis Resolution. *Gastroenterology* 158, 1728-1744.e14. <https://doi.org/10.1053/j.gastro.2020.01.027>
- Madsen, B.S., Thiele, M., Detlefsen, S., Kjærgaard, M., Møller, L.S., Trebicka, J., Nielsen, M.J., Stæhr, N., Leeming, D.J., Karsdal, M.A., Krag, A., 2021. C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol- related liver disease 699–708. <https://doi.org/10.1111/apt.16513>
- Mak, A.L., Lee, J., Dijk, A. Van, Vali, Y., Aithal, G.P., Schattenberg, J.M., Anstee, Q.M., Brosnan, M.J., Zafarmand, M.H., Ramssoekh, D., Harrison, S.A., Nieuwdorp, M., Bossuyt, P.M., Holleboom, A.G., 2021a. Systematic Review with Meta-Analysis : Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease 1–14.
- Moosavy, S.H., Eftekhari, E., Davoodian, P., Nejatizadeh, A., Shadman, M., 2023. AST / ALT ratio , APRI , and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas , Hormozgan , Iran 1–7.
- Nielsen, Mette J., Dolman, G.E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J.I., Irving, L., Karsdal, M.A., Patel, K., Leeming, D.J., Guha, I.N., Irving, W.L., Karsdal, M.A., Patel, K., Leeming, D.J., Guha, I.N., 2023. PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease Authors patients with advanced liver disease. *J. Hepatol.* 5, 100743. <https://doi.org/10.1016/j.jhepr.2023.100743>
- Nielsen, M.J., Leeming, D.J., Goodman, Z., Lefebvre, E., Sanyal, A.J., Ratziu, V., 2021. Comparison of ADAPT , FIB-4 and APRI as non-invasive predictors of liver fi brosis and NASH within the CENTAUR screening population. *J. Hepatol.* 75, 1292–1300. <https://doi.org/10.1016/j.jhep.2021.08.016>
- Rinaldi, L., Giorgione, C., Mormone, A., Esposito, F., Rinaldi, M., Berretta, M., Marfella, R., Romano, C., 2023. Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography : A Narrative Review 1–23.
- Samuel, J., Diana, J., Ahmed, M., Mette, J., Morten, A., Jane, I., Neil, I., Boer, D., Guruprasad, P., Leon, A., 2026. An algorithm incorporating PRO-C3

- accurately identifies patients with NAFLD and advanced fibrosis.
<https://doi.org/10.1002/hep.30163>
- Smith-roberge, J., Forouzannia, F., Hamadeh, A., Feng, Z., 2025. Estimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada , 2007-2021 : Mathematical Framework Development 11, 1–13.
<https://doi.org/10.2196/66309>
- Somnay, K., Wadgaonkar, P., Sridhar, N., Roshni, P., Rao, N., Wadgaonkar, R., 2024. Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives. *Biomedicines* 12.
<https://doi.org/10.3390/biomedicines12102229>
- Sun, J., Guo, J., Annual, E., Change, P., Index, S., 2025. Global , Regional , and National Burden of Chronic Hepatitis B-Related Cirrhosis From 1990 to 2021 and Projections to 2050 : A Finding From the Global Burden of Disease Study 2021 1–13.
- Tang, L., Eslam, M., Wong, G.L., Zhu, P., Chen, S., Leeming, D.J., Karsdal, M., Li, G., Huang, O., Leung, H.H., Zhou, Y., Feng, Q., Jiang, P., Gao, L., Byrne, C.D., Targher, G., George, J., Wong, W., Zheng, M., Centre, S.L., Hospital, W., Kong, H., Kong, H., n.d. Among simple non-invasive scores , Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD 1–24.
- Tsuji, Y., Namisaki, T., Kaji, K., Takaya, H., Nakanishi, K., Sato, S., Saikawa, S., Sawada, Y., Kitagawa, K.O.U., Shimozato, N., Kawaratani, H., Moriya, K.E.I., Noguchi, R., Akahane, T., Mitoro, A., Yoshiji, H., 2020. Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B 985–995. <https://doi.org/10.3892/etm.2020.8798>
- Wang, J., Sun, X., Wei, S., Chen, X., Zhu, H., Liantang, Y., Bao, R., 2024. Noninvasive models for the prediction of liver fibrosis in patients with chronic hepatitis B 1–8.
- WHO, 2024. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection.
- Wondmeneh, T.G., Mekonnen, A.T., 2024. Epidemiology of hepatitis B virus infection among pregnant women in Africa : a systematic review and meta - analysis. *BMC Infect. Dis.* <https://doi.org/10.1186/s12879-024-09839-3>
- Yang, B., Yang, T., Hou, C., Li, Y., Wang, Q., 2025. Patients with chronic hepatitis B exhibiting significant inflammation and fibrosis should pay particular attention to the status of hepatic steatosis during antiviral therapy.
- Zhang, Y., Yang, J., Wan, Q., Gan, L., Liu, J., 2026. Non-invasive assessment of liver fibrosis staging in chronic hepatitis B patients : combining two-dimensional shear wave elastography with serum indicators 1–12.
<https://doi.org/10.3389/fmed.2025.1709007>